

BICO Group AB Nomination Committee 2024 AGM appointed

BICO Group's major owners have appointed a Nomination Committee and the Annual General Meeting of BICO Group AB will be held on May 20, 2024.

In accordance with the decision by the Annual General Meeting 2023 when the most recently adopted principles regarding the composition of the nomination committee was made, the Nomination Committee of BICO Group AB shall consist of four members appointed by the largest shareholders. The Chairman of the Board shall not be a member of the Nomination Committee but shall normally be co-opted to the meeting of the Nomination Committee.

The four largest shareholders who wish to participate in the committee are entitled to appoint one member each. In preparation for the 2024 Annual General Meeting the members of the Nomination Committee have been appointed based on the ownership structure as per September 30, 2023, and consists of:

- Mats Engström, nominated by Erik Gatenholm
- Jens M. Artelt, nominated by Sartorius Lab Holding GmbH
- Malin Björkmo, nominated by Handelsbanken Fonder
- Claes Dinkelspiel, nominated by Héctor Martínez
- Rolf Classon, Chairman of the Board of BICO Group AB (co-opted)

The Nomination Committee will prepare proposals for the Annual General Meeting 2024 regarding election of chairman/woman and other directors of the board, election of auditor, matters regarding fees, election of chairman/woman of the Annual General Meeting and resolution concerning the Nomination Committee.

Shareholders who wish to submit proposals to the Nomination Committee ahead of the Annual General Meeting 2024 are welcome to contact the Nomination Committee by email: ir@bico.com, Please write "To the Nomination Committee" in the subject line or per mail:

BICO Group AB
att. Nomination Committee
Långfilsgatan 9
412 77 Gothenburg
Sweden

Proposals shall be submitted in writing in due time before the Annual General Meeting, no later than February 6, 2024, to ensure that the proposals can be considered by the Nomination Committee.

For further information, please contact:
Lotta Bus, General Counsel, BICO Group AB
Telephone : +46 70 611 75 08
E-mail: lb@bico.com

About BICO

BICO is a leading provider of life science solutions and laboratory automation that enable more efficient development of new treatments with more specificity and less need for animal testing.

The company uses bioconvergence as its operating system, combining advanced technologies with biology to streamline and automate workflows within the pharmaceutical and biopharma industries.

With 32,000+ instruments installed in over 65 countries, BICO products and solutions are found in more than 3,500 laboratories, including the world's top 20 pharmaceutical companies, and have been cited in over 11,000 publications.

Operating through three business areas – Bioprinting, Biosciences and Bioautomation – the BICO Group strives towards the long-term ambition of enabling the reduction of the world's organ shortage and speeding up drug development to create the future of life-saving treatments.

BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. www.bico.com

Attachments

[BICO Group AB Nomination Committee 2024 AGM appointed](#)